Curie.Bio Raises $380M Pro Rata Series A Fund To Support Portfolio Companies Through Clinical Trials
2024年6月26日 - 8:00PM
ビジネスワイヤ(英語)
We’re excited to announce today that we have closed $380 million
for our latest fund, bringing the total funds raised by Curie.Bio
to nearly $1 billion. These funds will enable us to continue
investing in successful early-stage therapeutics companies on their
path to generating meaningful clinical data. We anticipate that the
majority of this capital will be directed towards Series A rounds
for clinical proof-of-concept studies, demonstrating clinical
benefits for patients.
Visit our website or read our post below to learn more about our
unique model and incredible team.
____________
Curie.Bio: a better VC model for all biotech founders
We built Curie.Bio to free the founders. Curie.Bio
significantly improves your ability to create impactful medicines
while minimizing long-term dilution. Our unparalleled team and
capital-efficient model provide you with immediate access to the
industry’s top drug hunters, operators, and R&D services from
day one.
With better planning and more progress at the seed stage, you’ll
have a significantly higher chance of a future where you retain
agency and upside from your company’s success. We’ve raised nearly
$1 billion to provide founders with the world’s best people and to
fund their companies from the idea stage to meaningful clinical
data.
What do we offer?
- Services from an unparalleled team: We provide all the
essential functions of a large biotech company, so you don't have
to build them yourself. Our 50-person team of experienced drug
hunters and biotech operators, typically inaccessible or too
expensive for small biotech companies, joined us full-time to
support our early-stage portfolio. They work as fully integrated
members of your team on a day-to-day basis. We leverage this
institutional IQ to make sure you have everything and everyone you
need to reach the milestones that unlock your next round of funding
at a higher valuation. We do real work.
- Co-Piloting: Our co-pilots help you define and execute
the best possible seed work plan. This group has made significant
contributions to 150+ clinical-stage drugs and 30+ registered
products. With expertise in the art of drug hunting, we help you
choose the best therapeutic targets and the right TPPs to enable
efficacy in the optimal indications. We guide you in setting
appropriate, value-inflecting milestones based on future investor
feedback and tailor experimental plans to achieve those milestones.
We evaluate each data readout with you to help determine which
experiments need to be adjusted from the initial plan. We monitor
and help you react to updates from your competitors to ensure
you’re always aiming for best-in-class.
- Founder Services: We support you in all aspects of
building your company so you can execute your plan more
efficiently. We interview drug discovery vendors and help you
select the ones that get shit done. We help identify the expertise
needed to support your key programs and access the right experts.
We help you source, recruit, interview, and hire top talent. We
help you run the fundraising process to maximize interest from
later-stage investors and partners.
- Excellence In Execution: We get the best people in the
world to help you make impactful medicines. This ensures our
invested capital drives the most progress.
- External R&D: With over 200 CRO partnerships, we’ve
turned the global vendor ecosystem into an on-demand R&D
service for our portfolio companies. This ensures you get the best
team at the best CRO to complete each experiment in your R&D
plan. Our scale provides leverage in pricing, quality, and speed
that small, early-stage companies cannot access alone.
- Drug Discovery All-Stars: We’ve created an optional,
fractional staffing service to help fill operational and scientific
gaps on your team. Our CXOs and Drug Makers in Residence are highly
skilled in the craft of drug making and help you execute
experimental plans.
What do we invest in? Our portfolio of 20 early-stage
therapeutics companies includes a wide diversity of founder
backgrounds, therapeutic areas, drug modalities, and geographies.
We invest in platform and asset-centric companies, and in either
case, each of the company’s programs must have blockbuster
potential ($1B peak sales) on their own.
How does our model work better for founders? We helped
our first portfolio company, Forward Therapeutics, develop
clinic-ready therapies with blockbuster potential in less than 18
months on just $8M of capital. That helped the founders to raise a
$50M Series A at an impressive 5-fold valuation step-up, enabling
them to retain substantial equity in their company.
We believe the single greatest unlock of innovation in biotech
over the next decade will come from giving founders with great
therapeutic ideas the support and access they need to build
successful companies.
Do you have a therapeutic idea worthy of funding? Connect
with Curie.Bio here.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625444674/en/
Dan Budwick 1AB dan@1abmedia.com